March 4 (Reuters) - Alphamab Oncology 9966.HK:
SEES PROFIT OF NOT LESS THAN RMB150.0 MILLION FOR YEAR
EXPECTED RESULT DUE TO THREE LICENSE COLLABORATIONS AND SALES REVENUE IN FY
Further company coverage: 9966.HK
((Reuters.Briefs@thomsonreuters.com;))